摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[[5-chloro-6-[(5-cyclopropyl-2H-pyrazol-3-yl)amino]-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol | 852443-24-4

中文名称
——
中文别名
——
英文名称
2-[[5-chloro-6-[(5-cyclopropyl-2H-pyrazol-3-yl)amino]-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol
英文别名
2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol
2-[[5-chloro-6-[(5-cyclopropyl-2H-pyrazol-3-yl)amino]-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol化学式
CAS
852443-24-4
化学式
C21H25ClFN7O2
mdl
——
分子量
461.927
InChiKey
KJZIVTDADVVLOO-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    32
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    131
  • 氢给体数:
    6
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    丝氨醇 、 5,6-dichloro-N4-(3-cyclopropyl-1H-pyrazol-5-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine 以 正丁醇 为溶剂, 生成 2-[[5-chloro-6-[(5-cyclopropyl-2H-pyrazol-3-yl)amino]-2-[[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl]amino]propane-1,3-diol
    参考文献:
    名称:
    Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases
    摘要:
    The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of IN (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.
    DOI:
    10.1021/jm800343j
点击查看最新优质反应信息

文献信息

  • Pyrazole derivatives as inhibitors of receptor tyrosone kinases
    申请人:Block Howard Michael
    公开号:US20070142413A1
    公开(公告)日:2007-06-21
    Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    描述了式(I)的化合物及其在抑制Trk活性方面的用途。
  • PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    申请人:Block Michael Howard
    公开号:US20100152219A1
    公开(公告)日:2010-06-17
    Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    描述了式(I)的化合物及其在抑制Trk活性方面的应用。
  • Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
    申请人:Loxo Oncology, Inc.
    公开号:US10370727B2
    公开(公告)日:2019-08-06
    Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    本文提供了治疗癌症受试者的方法、为癌症受试者选择治疗方法的方法、为不包括Trk抑制剂的治疗方法选择癌症受试者的方法、确定癌症受试者对Trk抑制剂治疗产生阳性反应的可能性的方法、预测Trk抑制剂对癌症受试者疗效的方法、确定受试者罹患Trk抑制剂抗性癌症风险的方法,以及根据从受试者样本中检测到的细胞具有NTRK1和/或NTRK2和/或NTRK3中至少一种点突变,确定受试者存在Trk抑制剂抗性癌症的方法。
  • EP1686999B1
    申请人:——
    公开号:EP1686999B1
    公开(公告)日:2009-07-01
  • Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain
    申请人:Claesson Alf
    公开号:US20090005396A1
    公开(公告)日:2009-01-01
    This invention relates to the use of a pyrazolyl-pyrimidine of the formula (I). n=0, 1, 2 or 3 (I) in the manufacture of a medicament for use in the treatment or prophylaxis of pain. and to their pharmaceutical formulations and to their methods of use.
查看更多